Literature DB >> 9413221

5-fluorouracil (5-FU) and 5,10-methylene tetrahydrofolate (5,10-CH2FH4) as adjuvant therapy in an experimental rodent colon carcinoma model.

G Carlsson1, L O Hafström, C P Spears, B Gustavsson, P A Larsson.   

Abstract

Eradication of micrometastases is the goal for adjuvant therapy following a radical surgical procedure for cancer. We report an experimental study with 5,10-methylenetetrahydrofolate (5,10-CH2FH4) modulation of 5-fluorouracil (5-FU) cytotoxicity in adjuvant treatment. A colon adenocarcinoma cell suspension was inoculated intrahepatically in a rodent experimental model. Intravenous 5-FU (30 mg/kg) in combination with 5,10-CH2FH4 (15 mg/kg or 30 mg/kg) was administered after 1, 2, 3, 4 and 7 days. 5-FU alone reduced the tumor take to fifty percent compared to one hundred percent tumor take in control animals (p < 0.05), while 5-FU in combination with 5,10-CH2FH4 (regardless of folate-dose) eliminated tumor take (p < 0.0001). This makes 5,10-CH2FH4 a promising agent for modulation of 5-FU cytotoxicity in adjuvant cancer treatment.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9413221

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  3 in total

1.  MTHFR polymorphisms in relation to ovarian cancer risk.

Authors:  Kathryn L Terry; Shelley S Tworoger; Ellen L Goode; Margaret A Gates; Linda Titus-Ernstoff; Linda E Kelemen; Thomas A Sellers; Susan E Hankinson; Daniel W Cramer
Journal:  Gynecol Oncol       Date:  2010-11       Impact factor: 5.482

2.  Folate intake and methylenetetrahydrofolate reductase gene polymorphisms as predictive and prognostic biomarkers for ovarian cancer risk.

Authors:  Li Zhang; Wenxin Liu; Quan Hao; Lewen Bao; Ke Wang
Journal:  Int J Mol Sci       Date:  2012-03-23       Impact factor: 6.208

3.  Phase 1 dose de-escalation trial of the endogenous folate [6R]-5,10-methylene tetrahydrofolate in combination with fixed-dose pemetrexed as neoadjuvant therapy in patients with resectable rectal cancer.

Authors:  Bengt Gustavsson; Göran Carlsson; Torbjörn Swartling; Göran Kurlberg; Kristoffer Derwinger; Hillevi Björkqvist; Elisabeth Odin; Fernando Gibson
Journal:  Invest New Drugs       Date:  2015-07-21       Impact factor: 3.850

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.